A Phase 4 interventional study of Dapagliflozin (10Mg Tab) along with standard medical therapy and Empagliflozin (25 Mg Tab) along with standard medical therapy in Type 2 Diabetes, sponsored by Bhavya Bhavya, MD. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by Bhavya Bhavya, MD · Phase 4, Interventional, and Treatment
This study aims to compare the effect of two drugs used to treat diabetes, that is, Dapagliflozin and Empagliflozin on HbA1c (which is an indicator of blood sugar over the last 3 months) body weight, liver and kidney function, blood pressure, and overall cost-effectiveness in patients with type 2 diabetes and high body mass index (23kg/m2). The results will help us determine which drug is more effective, safer, and economical for Indian patients and improve future treatment options.
The convergence of India's diabetes epidemic, high rates of obesity and MASLD, and the availability of pleiotropic SGLT2 inhibitors presents both an opportunity and a challenge for optimal diabetes management. While both dapagliflozin and empagliflozin provide significant benefits over and above glycemic control, the absence of direct comparative data in Indian populations limits evidence-based treatment decisions. This study aims to address these critical knowledge gaps by delivering comprehensive comparative effectiveness and cost-effectiveness data to inform clinical practice and healthcare policy in India.
Despite extensive evidence supporting the use of SGLT2 inhibitors, several important knowledge gaps remain, especially in relation to Indian clinical practice.
This study is uniquely positioned to address this gap by conducting a head-to-head, RCT of dapagliflozin vs. empagliflozin in Indian adults with T2DM and high BMI. The design ensures standardized background therapy, minimizes bias, and includes a comprehensive evaluation of metabolic (HbA1c, weight), hepatic (CAP and LSM), renal, and cardiovascular outcomes, as well as adverse events and patient-reported tolerability. Furthermore, it incorporates a pharmacoeconomic analysis using Average and Incremental Cost-Effectiveness Ratios (ACER, ICER) to assess affordability and value, a key consideration in India and other low- and middle-income countries (LMICs).
By generating robust, context-specific data on comparative efficacy and value of these agents, this study aims to fill a crucial knowledge gap and support personalized clinical decision-making. It is thus expected to make a meaningful contribution to optimizing diabetes care in India.
9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.
This study's planned enrollment of 112 is above the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →This is the only study on the registry with Bhavya Bhavya, MD as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Adults aged 18 years or older with a diagnosis of type 2 diabetes mellitus (T2DM) who have been on stable background therapy for at least three months were eligible for inclusion. Participants were required to have an HbA1c level between 7% and 10% while receiving Metformin with or without other oral hypoglycemic agents, and there had to be a clear clinical indication to initiate an SGLT2 inhibitor. Individuals with a body mass index (BMI) of 23 kg/m² or higher and who were willing to provide written informed consent were included in the study.
Exclusion Criteria:
Patients were excluded if they had uncontrolled diabetes with an HbA1c level greater than 10.0% or if they had used SGLT2 inhibitors, insulin, or GLP-1 receptor agonists within 90 days prior to randomization. Individuals with a history of bariatric surgery or those planning such surgery during the study period were not eligible. Current alcohol consumption of ≥140 g/week in women or ≥210 g/week in men-equivalent to at least 14 or 21 standard drinks per week, respectively-was also an exclusion criterion. Acutely ill patients visiting the OPD, those receiving medications known to cause hepatic steatosis (such as amiodarone, valproate, tamoxifen, methotrexate, or steroids), and individuals with an eGFR \<45 mL/min/1.73 m² were excluded. Patients with contraindications to SGLT2 inhibitor use, including a history of recurrent urinary or genital infections, current or previous gangrene, known hypersensitivity to the drug, or a history of diabetic ketoacidosis, were also not included. Pregnant or breastfeeding women were excluded from participation.
Dapagliflozin 10 mg given once daily per orally for 6 months
Drug: Dapagliflozin (10Mg Tab) along with standard medical therapy
Empagliflozin 25mg given once daily per orally for 6 months
Drug: Empagliflozin (25 Mg Tab) along with standard medical therapy
Group A: Dapagliflozin 10 mg once daily + Metformin ± OHAs
Group B: Empagliflozin 25 mg once daily + Metformin ± OHAs
Change in HbA1c from baseline at 6 months
Time frame: From enrollment to the end of treatment at 6 months
Change in weight from baseline at 6 months
Time frame: From enrollment to the end of treatment at 6 months
Change in HbA1c (%) from baseline at 3 months
Time frame: From enrollment to the end of treatment at 3 months
Change in FBG (mg/dL) from baseline at 6 months
Time frame: From enrollment to the end of treatment at 6 months
Change in ALT from baseline at 6 months
Time frame: From enrollment to the end of treatment at 6 months
Changes in LSM from baseline at 6 months
Time frame: From enrollment to the end of treatment at 6 months
Change in SBP (mmHg) from baseline at 6 months
Time frame: From enrollment to the end of treatment at 6 months
Change in serum creatinine (mg/dL) from baseline at 6 months
Time frame: From enrollment to the end of treatment at 6 months
Incidence of adverse events from baseline at 6 month
Time frame: From enrollment to the end of treatment at 6 months
Incidence of Drug-related Discontinuation at 6 month
Time frame: From enrollment to the end of treatment at 6 months
Change in AST from baseline at 6 months
Time frame: From enrollment to the end of treatment at 6 months
Changes in CAP from baseline at 6 months
Time frame: From enrollment to the end of treatment at 6 months
Change in GGT from baseline at 6 months
Time frame: From enrollment to 6 months
Change in DBP (mmHg) from baseline at 6 months
Time frame: From enrollment to end of treatment at 6 months
Change in eGFR from baseline at 6 months
Time frame: From enrollment to end of treatment at 6 months
Change in UACR (mg/g) from baseline at 6 months
Time frame: From enrollment to end of treatment at 6 months
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.